PHYSIOLOGICAL BASIS OF ALZHEIMER'S DISEASE
Abstract
Alzheimer's disease is a chronic, progressive neurodegenerative disease of the central nervous system, which is mainly characterized by impaired cognitive functions, memory, thinking and behavior. This article provides an in-depth analysis of the physiological basis of Alzheimer's disease, that is, its cellular and molecular mechanisms. In particular, the accumulation of beta-amyloid peptides, pathological phosphorylation of tau proteins, disruption of interneuronal synaptic transmission and neuroinflammation processes are considered. The role of oxidative stress, mitochondrial dysfunction and genetic factors is also analyzed. The results of the study show that several pathophysiological mechanisms are involved in the development of Alzheimer's disease in an interconnected manner. The article is of great importance in improving early detection, prevention and treatment strategies of the disease. This scientific work will serve as a useful resource for specialists, students and researchers working in the fields of medicine and biology.
References
1. Selkoe D.J. (2001). Alzheimer's disease: Genes, proteins, and therapy. Physiological Reviews.
2. Hardy J., Selkoe DJ. (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems. Science.
3. Querfurth H.W., LaFerla F.M. (2010). Alzheimer's disease. New England Journal of Medicine.
4. Jack C.R. et al. (2013). Tracking pathophysiological processes in Alzheimer's disease. Lancet Neurology.
5. De Strooper B., Curran E. (2016). The cellular phase of Alzheimer's disease. Cell.
6. World Health Organization (2019). Dementia: A Public Health Priority.
7. Alzheimer's Association (2023). Alzheimer's disease facts and figures.
8. Bloom G.S. (2014). Amyloid-b and tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurology.
9. Huang Y., Mucke L. (2012). Alzheimer mechanisms and therapeutic strategies. Cell.
10. Scheltens P. et al. (2021). Alzheimer's disease. The Lancet.
11. Serrano-Pozo A. et al. (2011). Neuropathological alterations in Alzheimer's disease. Cold Spring Harbor Perspectives in Medicine.
12. Lane C.A., Hardy J., Schott J.M. (2018). Alzheimer's disease. European Journal of Neurology.
13. Busche M.A., Hyman B.T. (2020). Synergy between amyloid-b and tau in Alzheimer's disease. Nature Neuroscience.
14. Tönnies E., Trushina E. (2017). Oxidative stress, synaptic dysfunction, and Alzheimer's disease. Journal of Alzheimer's Disease.
15. Swerdlow R.H. (2018). Mitochondria and mitochondrial cascades in Alzheimer's disease. Journal of Alzheimer's Disease.
16. Heneka M.T. et al. (2015). Neuroinflammation in Alzheimer's disease. Lancet Neurology.
17. Masters C.L. et al. (2015). Alzheimer's disease. Nature Reviews Disease Primers.
18. Cummings J., Lee G., Ritter A., Zhong K. (2020). Alzheimer's disease drug development pipeline. Alzheimer's & Dementia.
19. Bateman R.J. et al. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. New England Journal of Medicine.
20. Glenner G.G., Wong C.W. (1984). Alzheimer's disease and Down's syndrome: Sharing amyloid protein. Biochemical and Biophysical Research Communications.
